Detection of alternative lengthening of telomeres mechanism on tumor sections.

ALT xenograft Alternative lengthening of telomeres Native telomeric FISH Paediatric tumor Telomere

Journal

Molecular biomedicine
ISSN: 2662-8651
Titre abrégé: Mol Biomed
Pays: Singapore
ID NLM: 9918283581406676

Informations de publication

Date de publication:
20 Oct 2021
Historique:
received: 05 07 2021
accepted: 14 09 2021
entrez: 10 1 2022
pubmed: 11 1 2022
medline: 11 1 2022
Statut: epublish

Résumé

The vast majority of adult cancer cells achieve cellular immortality by activating a telomere maintenance mechanism (TMM). While this is mostly achieved by the de-silencing of hTERT telomerase gene expression, an alternative homologous recombination-based and telomerase-independent mechanism, known as ALT (Alternative Lengthening of Telomeres), is frequently activated in a subset of tumors, including paediatric cancers. Being absent from normal cells, the ALT mechanism offers interesting perspectives for new targeted cancer therapies. To date, however, the development of better translationally applicable tools for ALT detection in tumor sections is still needed. Here, using a newly derived ALT-positive cancer cell mouse xenograft model, we extensively examined how the previously known ALT markers could be used as reliable tools for ALT diagnosis in tumor sections. We found that, together with the detection of ultra-bright telomeric signals (UBS), an ALT hallmark, native telomeric FISH, that detects single-stranded C-rich telomeric DNA, provides a very sensitive and robust tool for ALT diagnosis in tissues. We applied these assays to paediatric tumor samples and readily identified three ALT-positive tumors for which the TMM was confirmed by the gold-standard C-circle amplification assay. Although the latter offers a robust assay for ALT detection in the context of research laboratories, it is more difficult to set up in histopathological laboratories and could therefore be conveniently replaced by the combination of UBS detection and native telomeric FISH.

Identifiants

pubmed: 35006465
doi: 10.1186/s43556-021-00055-y
pii: 10.1186/s43556-021-00055-y
pmc: PMC8607387
doi:

Types de publication

Journal Article

Langues

eng

Pagination

32

Subventions

Organisme : fonds de la recherche scientifique - fnrs
ID : 7.6519.20
Organisme : fondation contre le cancer (be)
ID : 2018-072-project # FAF-F/208/1208
Organisme : king baudouin foundation (be)
ID : 2016-J1151710-206515

Informations de copyright

© 2021. The Author(s).

Références

EMBO J. 2021 Mar 15;40(6):e106336
pubmed: 33595114
Mol Cell Oncol. 2019 Sep 11;6(6):e1651603
pubmed: 31692925
Clin Cancer Res. 2005 Jan 1;11(1):217-25
pubmed: 15671549
N Engl J Med. 2015 Sep 3;373(10):908-19
pubmed: 26332545
Oncogene. 2005 Nov 24;24(53):7893-901
pubmed: 16116482
Oncogene. 2009 Apr 9;28(14):1682-93
pubmed: 19252523
N Engl J Med. 2015 Sep 3;373(10):920-8
pubmed: 26332546
Br J Cancer. 2013 Oct 15;109(8):2228-36
pubmed: 24064976
Cell Rep. 2017 Jun 20;19(12):2529-2543
pubmed: 28636941
Cancer Res. 2005 Apr 1;65(7):2722-9
pubmed: 15805271
Genes Dev. 2020 May 1;34(9-10):650-662
pubmed: 32217664
Nucleic Acids Res. 2013 Jan;41(2):e34
pubmed: 22923525
Ann Oncol. 1997 Dec;8(12):1221-8
pubmed: 9496387
Lab Invest. 2011 Aug;91(8):1195-205
pubmed: 21519327
Science. 2012 Jun 15;336(6087):1388-90
pubmed: 22700908
J Neurooncol. 2017 Nov;135(2):381-390
pubmed: 28755323
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncogene. 2016 Apr 7;35(14):1811-21
pubmed: 26119943
Methods. 2017 Feb 1;114:74-84
pubmed: 27595911
Nucleic Acids Res. 2014 Apr;42(7):4391-405
pubmed: 24500201
BMC Cancer. 2010 Jun 03;10:254
pubmed: 20525266
Am J Pathol. 2011 Oct;179(4):1608-15
pubmed: 21888887
Nat Biotechnol. 2009 Dec;27(12):1181-5
pubmed: 19935656
Neuro Oncol. 2012 Jun;14(6):736-44
pubmed: 22516689
Cancer Res. 2005 Apr 1;65(7):2730-7
pubmed: 15805272
Cancer Res. 2020 Jun 15;80(12):2663-2675
pubmed: 32291317
Mol Cell. 2019 Aug 8;75(3):469-482.e6
pubmed: 31278054
Nat Commun. 2021 Jan 4;12(1):92
pubmed: 33397920
Curr Opin Genet Dev. 2020 Feb;60:1-8
pubmed: 32114293
Curr Opin Genet Dev. 2020 Feb;60:25-30
pubmed: 32119936

Auteurs

Eloïse Claude (E)

Genetic & Epigenetic Alterations of Genomes Unit, de Duve Institute, UCLouvain, Brussels, Belgium.

Guillaume de Lhoneux (G)

Genetic & Epigenetic Alterations of Genomes Unit, de Duve Institute, UCLouvain, Brussels, Belgium.

Christophe E Pierreux (CE)

Cell Unit, de Duve Institute, UCLouvain, Brussels, Belgium.

Etienne Marbaix (E)

Cell Unit, de Duve Institute, UCLouvain, Brussels, Belgium.
Department of Anatomopathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Maëlle de Ville de Goyet (M)

Department of Paediatric Haematology and Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

Cécile Boulanger (C)

Department of Paediatric Haematology and Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

An Van Damme (A)

Department of Paediatric Haematology and Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

Bénédicte Brichard (B)

Department of Paediatric Haematology and Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

Anabelle Decottignies (A)

Genetic & Epigenetic Alterations of Genomes Unit, de Duve Institute, UCLouvain, Brussels, Belgium. anabelle.decottignies@uclouvain.be.

Classifications MeSH